ARTIVA BIOTHERAPEUTICS Stock Price, News & Analysis

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) is a clinical-stage biotechnology company in the healthcare sector focused on developing cell therapies for patients with devastating autoimmune diseases and cancers. According to company disclosures, Artiva’s mission is to develop effective, safe and accessible cell therapies, with a particular emphasis on natural killer (NK) cell–based approaches for B‑cell driven disease.

Artiva’s lead program is AlloNK (also known as AB‑101), described as an allogeneic, off‑the‑shelf, non‑genetically modified, cryopreserved NK cell therapy candidate. Company materials state that AlloNK is designed to enhance the antibody‑dependent cellular cytotoxicity (ADCC) effect of monoclonal antibodies to drive B‑cell depletion. AlloNK is being evaluated in multiple ongoing clinical trials for B‑cell driven autoimmune diseases, where it is administered in combination with anti‑CD20 monoclonal antibodies such as rituximab or obinutuzumab following a conditioning regimen with cyclophosphamide and fludarabine.

Clinical focus and indications

Artiva reports that AlloNK is currently being explored in Phase 1 and 2 trials across several autoimmune indications, including refractory rheumatoid arthritis (RA), Sjögren’s disease (SjD), systemic lupus erythematosus (SLE), lupus nephritis (LN), idiopathic inflammatory myopathies and systemic sclerosis (SSc). The company describes these as B‑cell driven autoimmune diseases with significant unmet need, particularly in patients who remain refractory after multiple prior therapies.

Artiva has disclosed that it has prioritized refractory rheumatoid arthritis as the lead indication for AlloNK. Company announcements state that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AlloNK for the treatment of refractory RA in combination with rituximab, and that AlloNK is believed by the company to be the first drug candidate in the emerging deep B‑cell depleting category to receive this designation in RA. Artiva highlights the opportunity to address patients who have failed at least two biologic or targeted synthetic disease‑modifying anti‑rheumatic drugs.

AlloNK treatment regimen and mechanism

In its public communications and SEC filings, Artiva explains that patients in its ongoing trials receive a standard conditioning regimen of cyclophosphamide and fludarabine prior to AlloNK administration. AlloNK is given as three weekly doses and combined with an anti‑CD20 monoclonal antibody, either rituximab or obinutuzumab, in an outpatient setting. Initial safety and translational data reported by the company describe AlloNK as an allogeneic, off‑the‑shelf NK cell therapy intended to enhance the activity of B‑cell‑targeting antibodies through ADCC, with the goal of achieving deep and consistent B‑cell depletion.

Artiva has reported initial safety and translational findings in autoimmune disease, including data from dozens of patients treated with AlloNK plus anti‑CD20 therapy across RA, SjD, SLE, LN and SSc. Company disclosures indicate that, as of a specified data cutoff, patients were treated as outpatients, most at community rheumatology trial sites without specialized oncology oversight, and that the regimen was generally well tolerated with no AlloNK‑related Grade 3 or higher treatment‑emergent adverse events reported in that dataset. Translational data described by Artiva show non‑quantifiable peripheral CD19+ B‑cell levels by Day 13 of treatment in analyzed patients, including when assessed with a high‑sensitivity assay, which the company cites as supporting AlloNK’s intended mechanism of action.

Pipeline beyond AlloNK

In addition to AlloNK, Artiva states that its pipeline includes CAR‑NK candidates targeting both solid and hematologic cancers. These chimeric antigen receptor NK cell programs are presented by the company as part of its broader effort to apply NK cell technology to oncology, although detailed product‑specific information is not provided in the supplied materials.

Origins and partnerships

Artiva reports that it was founded in 2019 as a spin‑out of GC Cell, formerly GC Lab Cell Corporation, a healthcare company in the Republic of Korea. Under a strategic partnership, Artiva states that it holds exclusive worldwide rights, excluding Asia, Australia and New Zealand, to GC Cell’s NK cell manufacturing technology and programs. This relationship underpins the company’s access to NK cell manufacturing capabilities for its clinical‑stage and pipeline programs.

The company is incorporated in Delaware and, according to its public disclosures, is headquartered in San Diego, California. Artiva’s common stock trades on the Nasdaq Global Market under the ticker symbol ARTV.

Corporate and regulatory disclosures

Artiva regularly files reports with the U.S. Securities and Exchange Commission (SEC), including Form 8‑K current reports describing clinical, regulatory, financial and corporate governance developments. Recent filings referenced in the available data include disclosures of clinical data for AlloNK in autoimmune disease, quarterly financial results, equity incentive plan amendments and equity award exchanges for certain executives. These filings provide additional detail on the company’s operations, clinical progress and capital structure.

Through its focus on NK cell–based therapies, Artiva positions itself, in its own materials, as a clinical‑stage biotechnology company working to make cell therapies more accessible for patients with serious autoimmune conditions and cancers, particularly in settings such as community rheumatology clinics where outpatient administration is important.